bremelanotide
ProductHeard on podcasts recently
A melanocortin receptor agonist marketed as Vyleesi and approved in the United States for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women.
Discussed inHealth & Science100%
Rank this week
—
Not in this week’s list
Share of the conversation
—
Reach this week
—
Tone this week
—
Not enough signal yet (fewer than 3 episodes scored).
Share of the conversation
Mentions of bremelanotide per 1,000 mentions of anything, 7-day rolling, all podcasts.
Show the data
| Day | Share (7-day) | Mentions |
|---|---|---|
| Aug 8 | 0.07‰ | 1 |
| Aug 25 | 0.07‰ | 2 |
| Sep 1 | 0.03‰ | 1 |
| Sep 9 | 0.04‰ | 1 |
Discussed alongside
Names that come up in the same conversations as bremelanotide.
Embed this
Paste this on your site to show bremelanotide's current trend:
<iframe src="https://podlume.ai/embed/e/bremelanotide" width="360" height="220" style="border:0" loading="lazy" title="bremelanotide on PodLume Trends"></iframe>